McDonnell Boehnen Hulbert & Berghoff LLP partner Kevin Noonan, Ph.D. is quoted in a July 2, 2018 BioProcess Insider article entitled, “Humira Biosimilars: Amgen Lawsuit ‘Stake in the Ground’ for Others.” Amgen will challenge AbbVie’s bestseller Humira in the US from 2023, following a lawsuit settled last year. Other adalimumab developers are likely to receive the same deal, an IP lawyer says. View the article